EDIT - Editas Medicine Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)
2024-02-07 14:00:23 ET
Editas Medicine, Inc. (EDIT)
Guggenheim 6th Annual Biotechnology Conference
February 07, 2024 09:30 AM ET
Company Participants
Gilmore O'Neill - President and CEO
Conference Call Participants
Debjit Chattopadhyay - Guggenheim
Presentation
Debjit Chattopadhyay
Good morning. Thank you for joining the Guggenheim Securities Healthcare team at our 6th Annual Conference. I'm Debjit and joining us from Editas Medicine is its President and CEO, Gilmore O'Neill.
Thank you so much for your time Gilmore. And if we could start off with a very quick overview of Editas.
Gilmore O'Neill
Sure. Good morning and thanks very much Debjit. Great to be here. Editas is a clinical stage company, specializing in programmable CRISPR mediated gene editing, our lead program is a reni-cel, a cell based edited therapy for the treatment of hemoglobinopathies encompassing sickle cell disease and beta thalassemia....
Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)